EcoDrugPlus

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSIPUG00000006963
Gene Symbol: FGFR3
4 Cross references
193 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSIPUG00000009753
Gene Symbol: FLT1
3 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSIPUG00000016925
Gene Symbol: FLT4
3 Cross references
193 Possible Orthologues:

Folate Receptor

Ensembl ID : ENSIPUG00000014768
Gene Symbol: FOLR
4 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSIPUG00000008746
Gene Symbol: FSHR
3 Cross references
200 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSIPUG00000023259
Gene Symbol: LOC108256689
3 Cross references
304 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSIPUG00000023265
Gene Symbol: LOC108256693
2 Cross references
304 Possible Orthologues:

Free Fatty Acid Receptor 3

Ensembl ID : ENSIPUG00000023266
Gene Symbol: LOC108256150
3 Cross references
338 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSIPUG00000001638
Gene Symbol: FRK
2 Cross references
209 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 1b

Ensembl ID : ENSIPUG00000015929
Gene Symbol: GABBR1B
2 Cross references
191 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSIPUG00000022556
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2

Ensembl ID : ENSIPUG00000020363
Gene Symbol: LOC108268623
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).